BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37174067)

  • 21. BODY COMPOSITION IMPACT ON SURVIVAL AND TOXICITY OF TREATMENT IN PANCREATIC CANCER: CROSS-SECTIONAL PILOT STUDY.
    BarrÈre APN; Piovacari SMF; UsÓn Junior PLS; Gansl RC; Pereira AZ; Hamerschlak N
    Arq Gastroenterol; 2020; 57(3):278-282. PubMed ID: 33027479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
    Mardas M; Stelmach-Mardas M; Madry R
    Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computed tomography-measured body composition parameters do not influence survival in non-metastatic colorectal cancer.
    Cárcamo L; Peñailillo E; Bellolio F; Miguieles R; Urrejola G; Zúñiga A; Molina ME; Larach JT
    ANZ J Surg; 2021 May; 91(5):E298-E306. PubMed ID: 33682291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High visceral fat-to-muscle ratio is an independent factor that predicts worse overall survival in patients with primary epithelial ovarian, fallopian tube, and peritoneal cancer.
    Ham S; Choi JH; Shin SG; Lee EJ
    J Ovarian Res; 2023 Jan; 16(1):19. PubMed ID: 36681847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
    Charette N; Vandeputte C; Ameye L; Bogaert CV; Krygier J; Guiot T; Deleporte A; Delaunoit T; Geboes K; Van Laethem JL; Peeters M; Demolin G; Holbrechts S; Flamen P; Paesmans M; Hendlisz A
    BMC Cancer; 2019 Feb; 19(1):134. PubMed ID: 30744591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients.
    Wang Y; Thai T; Moore K; Ding K; McMeekin S; Liu H; Zheng B
    Oncol Lett; 2016 Jul; 12(1):680-686. PubMed ID: 27347200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of CT-Determined Sarcopenia and Body Composition on Survival Outcome in Patients with Advanced-Stage High-Grade Serous Ovarian Carcinoma.
    Kim SI; Kim TM; Lee M; Kim HS; Chung HH; Cho JY; Song YS
    Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32121099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
    Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
    Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
    Franzoi MA; Vandeputte C; Eiger D; Caparica R; Brandão M; De Angelis C; Hendlisz A; Awada A; Piccart M; de Azambuja E
    Breast Cancer Res Treat; 2020 May; 181(1):199-209. PubMed ID: 32246377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations of muscle and adipose tissue parameters with long-term outcomes in middle and low rectal cancer: a retrospective cohort study.
    Liu J; Yu X; Huang X; Lai Q; Chen J
    Cancer Imaging; 2023 Jan; 23(1):5. PubMed ID: 36635737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computed Tomography-Based Body Composition Is Not Consistently Associated with Outcome in Older Patients with Colorectal Cancer.
    Looijaard SMLM; Meskers CGM; Slee-Valentijn MS; Bouman DE; Wymenga ANM; Klaase JM; Maier AB
    Oncologist; 2020 Mar; 25(3):e492-e501. PubMed ID: 32162794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Body Composition Changes Detected by [
    Albano D; Dondi F; Treglia G; Tucci A; Ravanelli M; Farina D; Bertagna F
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
    Young AC; Quach HT; Song H; Davis EJ; Moslehi JJ; Ye F; Williams GR; Johnson DB
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32747470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma.
    Gerestein CG; Eijkemans MJ; de Jong D; van der Burg ME; Dykgraaf RH; Kooi GS; Baalbergen A; Burger CW; Ansink AC
    BJOG; 2009 Feb; 116(3):372-80. PubMed ID: 19187369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
    Yu W; Ye Z; Fang X; Jiang X; Jiang Y
    J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.